Accessibility Statement Skip Navigation
  • Back to Global Sites
  • +972-77-2005042
  • Blog
  • Journalists
  • GDPR
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • Telephone

      • +972-77-2005042 from 8 AM - 11 PM IL

      • Contact
      • Contact

        +972-77-2005042
        from 8 AM - 11 PM IL

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Request More Information
      • Journalists
      • GDPR

      Hadassah Cancer Research Institute (HCRI) Announces Groundbreaking Advance in Personalized Cancer Care


      News provided by

      The Hadassah Cancer Research Institute

      23 Jul, 2024, 15:00 IDT

      Share this article

      Share this article


      JERUSALEM, July 23, 2024 /PRNewswire/ -- Hadassah Cancer Research Institute (HCRI), a leading force in advancing cancer treatments, unveils a significant breakthrough in personalized cancer care. This research, published in the esteemed journal Cell Reports Medicine (June 11, 2024), introduces MESiCA, a novel machine learning model poised to revolutionize cancer diagnosis and treatment.

      "This publication represents a major leap forward in personalized medicine," emphasizes Professor Michal Lotem, Head of HCRI. "MESiCA offers a practical tool for oncologists, enabling them to make more informed decisions, ultimately leading to improved patient outcomes."

      Unlocking the Potential of Mutational Signatures

      Cancer development is driven by mutations in the DNA, leaving behind unique patterns known as "mutational signatures." These signatures act as fingerprints, revealing the underlying causes of the cancer. Some of these fingerprints have clinical implications for treatment plans. Traditionally, identifying these signatures required analysing a vast amount of data, often exceeding what's available in routine clinical settings.

      "Current methods rely on targeted gene panel testing, which only analyses a small portion of the genome," explains Professor Aron Popovtzer, Heading the Sharett oncology institute. "This limitation hindered our ability to detect mutational signatures and apply this information to personalize treatment plans."

      MESiCA: A Game-Changer for Personalized Care

      MESiCA tackles this challenge by harnessing the power of machine learning and natural language processing (NLP). This innovative model can accurately detect dominant mutational signatures using only a small number of mutations, making it ideal for everyday clinical use.

      "MESiCA has been validated in over 60,000 cancer samples, revealing crucial signatures linked to better survival rates and treatment responses," highlight Dr. Adar Yaacov, the 1st author, and Dr. Shai Rosenberg (head of the Laboratory for Cancer Computational Biology), the principle investigator of this project. "By enabling the detection of these signatures in routine tests, MESiCA empowers clinicians to prescribe more accurate personalize treatment plans, ultimately improving patient outcomes."

      This groundbreaking research by Dr. Rosenberg and Dr. Yaacov paves the way for a new era of personalized cancer care. With MESiCA, HCRI continues its unwavering commitment to developing innovative solutions to combat cancer. http://www.h-cri.org

      SOURCE The Hadassah Cancer Research Institute

      Modal title

      Contact PR Newswire

      • +972-77-2005042
        from 8 AM - 11 PM IL

      Global Sites

      • APAC
      • APAC - Traditional Chinese
      • Asia
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany

       

      • India
      • Indonesia
      • Israel
      • Italy
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland

       

      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • United States

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921
      Global Sites
      • Asia
      • Brazil
      • Canada
      • Csezh
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Israel
      • Italie
      • Mexico
      • Middle East
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • United States
      +972-77-2005042
      from 8 AM - 11 PM IL
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • Cookie Settings
      Copyright © 2026 Cision US Inc.